HOME > BUSINESS
BUSINESS
- AbbVie Files Maviret for Pediatric Use for Age 12 and Older
December 3, 2018
- Olympus to Launch Japan Clinical Study of Regenerative Medicine Product for Traumatic Cartilage Defects
December 3, 2018
- ADHD Treatments to Reap 50% Growth in 2026, Despite Shrinking CNS Market: Fuji Keizai
December 3, 2018
- US FDA Approves Astellas’ AML Treatment Xospata
November 30, 2018
- Celgene Files Otezla for Additional Indication of Oral Ulcers due to Behcet’s Disease
November 30, 2018
- JT to Return Rights to Gilead’s 6 HIV Agents in 2019, Get 63.1 Billion Yen
November 30, 2018
- Kowa Reps Continue Heavy GP Detailing for Parmodia in August: Anterio
November 30, 2018
- Fycompa Hits Primary Endpoint in Monotherapy PIII, Eisai Eyes Filing by March-End
November 29, 2018
- Daiichi Sankyo, Roche to Collaborate on CDx Development for DS-8201
November 29, 2018
- JCR Launches Japan’s 1st Fabrazyme Biosimilar
November 29, 2018
- Daiichi Sankyo’s Herceptin Biosimilar Hits Shelves, Nippon Kayaku/Celltrion Earn Breast Cancer Nod
November 29, 2018
- Takeda’s Brigatinib Bags European OK for 2nd Line ALK-Positive NSCLC
November 29, 2018
- Dissident Shareholder Group Hails Ex-Takeda Chief’s Opposition to Shire Deal
November 29, 2018
- Blincyto, Eybelis Now Available in Japan
November 28, 2018
- Ono Submits Cancer Cachexia Treatment in Japan
November 28, 2018
- Pola Orbis to Transfer All Shares of Pola Pharma to Sun Pharma Global, Aiming to Focus on Beauty Care Business
November 28, 2018
- Sumitomo Dainippon Settles Latuda Patent Lawsuits in US, New 5-Year Biz Plan Due Out Next Spring
November 28, 2018
- Keytruda Continues to Close in on Opdivo in July-September Global Sales
November 27, 2018
- Poteligeo Approved in Europe for Mycosis Fungoides, Sézary Syndrome: Kyowa Kirin
November 27, 2018
- HIV Drug Juluca Gets Japan Approval: ViiV
November 27, 2018
ページ
On paper, things should be looking up for Japan’s pharmaceutical wholesalers. Industry expectations are mounting that the average gap between NHI and market prices will narrow further in FY2026 from the previous year’s record low of 4.8%.A shrinking gap should…
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
